A strategy for collecting pharmacoeconomic data during phase II/III clinical trials

PharmacoEconomics

Volumn 9, Issue 3, 1996, Pages 264-277

  Mauskopf, Josephine ^a   Schulman, Kevin ^b   Bell, Larry ^c   Glick, Henry ^d  

^a GLAXOSMITHKLINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c University of Pennsylvania ^*

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; MARKET; METHODOLOGY; ORGANIZATION; PHARMACOECONOMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0029993789     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609030-00007     Document Type: Review

References (27)

1. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81
2. Evans D, Freund D, Dittus R, et al. The use of economic analysis as a basis for inclusion of pharmaceutical products on the pharmaceutical benefits scheme. Canberra: Department of Health, Housing and Community Services, 1990
3. Schulman K. The use of evaluation in pharmaceutical reimbursement decisions in the United States. In: Schubert F, editor. Proceedings of the Canadian Collaborative Workshop on Pharmacoeconomics; 1993 Jun 21-22; Quebec. Princeton (NJ): Excerpta Medica Inc., 1993: 19-23
4. Eisenberg J, Glick H, Schulman K, et al. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom B, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley and Sons Ltd, 1994
5. Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-73
6. Schulman K, Glick H, Buxton M, et al. Economic assessment of the FIRST study: a prospective multinational phase III study. Controlled Clin Trials. In press
7. Bonsel G, Rutten F, Uyl-de Groot C. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 1993; 29A Suppl. 7: S10-4
8. Morris J, Goddard M. Economic evaluations and quality of life assessments in cancer clinical trials: the CHART trial. Eur J Cancer 1993; 29A(5): 766-70
9. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analyses. N Engl J Med 1994; 331: 669-70
10. Schulman KA, Rubenstein LE, Glick HA, et al. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. PharmacoEconomics 1995; 7: 206-20
11. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 122: 61-70
12. Glick H. Strategies for economic assessment during the development of new drugs. Drug Info J 1995; 29: 1391-403
13. De Nino L, Mulrow C, Gerety M, et al. Problems in interpreting cost effectiveness in clinical trials: experimental versus implementation costs. Online J Curr Clin Trials 1993 Apr 10; Document no. 44
14. O'Brien B, Drummond M, Labelle R, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150-63
15. Schulman K, Yabroff K, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Info J 1995; 29: 1405-14
16. Copley-Merriman C, Lair T. Valuation of medical resource units collected in health economic studies. Clin Ther 1994; 16: 553-68
17. Revicki D, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994; 32: 401-4
18. Schron E, Shumaker S. The integration of health quality of life in clinical research: experiences from cardiovascular clinical trials. Prog Cardiovasc Nurs 1992; 7: 21-8
19. Cella D, Wiklund I, Shumaker S, et al. Integrating health-related quality of life into cross-national clinical trials. Qual Life Res 1993; 2: 433-40
20. Cunny K, Perri M. Single-item vs multiple-item measures of health-related quality of life. Psychol Rep 1991; 69: 127-30
21. Torrance G. Measurement of health states for economic appraisal. J Health Econ 1986; 5: 1-30
22. Kaplan R, Feeny D, Revicki D. Methods for assessing relative importance in preference based outcome measures. Qual Life Res 1993; 2: 467-75
23. Van Hout B, Al M, Gordon G, et al. Costs, effects, and c/e ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
24. Rutten-van Mölken M, van Doorslaer E, van Vliet R. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3: 333-45
25. Fenn P, McGuire A, Phillips V, et al. The analysis of censored treatment cost data in economic evaluation. Med Care 1995; 33:851-63
26. Finkler S. The distinction between cost and charges. Ann Intern Med 1982; 96: 102-9
27. Glick H, Heyse J, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992; 8: 719-34